Equities research analysts expect Omeros Co. (NASDAQ:OMER) to announce earnings of ($0.16) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Omeros’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.13). Omeros reported earnings of ($0.20) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 20%. The business is expected to issue its next quarterly earnings results on Thursday, March 15th.

On average, analysts expect that Omeros will report full-year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.01) to ($0.95). For the next year, analysts expect that the company will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.70) to ($0.24). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Omeros.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million for the quarter, compared to analyst estimates of $17.82 million. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. The company’s quarterly revenue was up 91.9% on a year-over-year basis.

A number of research analysts recently issued reports on the stock. Maxim Group set a $24.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Wednesday. HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Thursday. Zacks Investment Research downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Finally, Wedbush restated an “outperform” rating and set a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $34.14.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AMP Capital Investors Ltd acquired a new position in Omeros during the third quarter valued at $279,000. Stifel Financial Corp increased its holdings in Omeros by 10.7% in the third quarter. Stifel Financial Corp now owns 394,428 shares of the biopharmaceutical company’s stock valued at $8,522,000 after buying an additional 38,268 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Omeros by 10.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 217,804 shares of the biopharmaceutical company’s stock valued at $4,709,000 after buying an additional 20,139 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Omeros by 13.8% in the third quarter. Wells Fargo & Company MN now owns 42,144 shares of the biopharmaceutical company’s stock valued at $911,000 after buying an additional 5,102 shares in the last quarter. Finally, First Interstate Bank purchased a new position in Omeros in the third quarter valued at $108,000. Institutional investors own 49.71% of the company’s stock.

Omeros (NASDAQ OMER) traded down $0.28 during trading hours on Friday, hitting $19.42. 374,228 shares of the stock traded hands, compared to its average volume of 646,610. The firm has a market capitalization of $918.98, a P/E ratio of -15.05 and a beta of 3.56. Omeros has a 1-year low of $8.71 and a 1-year high of $27.09. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99.

TRADEMARK VIOLATION WARNING: This piece was posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.mareainformativa.com/analysts-anticipate-omeros-co-omer-will-post-earnings-of-0-16-per-share-updated-updated-updated/124412/.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.